BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone919-582-9050
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$55.64 million
Profitability
Miscellaneous
Employees164
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
BioDelivery Sciences International (NASDAQ:BDSI) Frequently Asked Questions
What is BioDelivery Sciences International's stock symbol?
BioDelivery Sciences International trades on the NASDAQ under the ticker symbol "BDSI."
How were BioDelivery Sciences International's earnings last quarter?
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced its earnings results on Thursday, August, 8th. The specialty pharmaceutical company reported $0.06 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.06) by $0.12. The specialty pharmaceutical company earned $29.68 million during the quarter, compared to analyst estimates of $25.30 million. BioDelivery Sciences International had a negative return on equity of 0.85% and a negative net margin of 34.73%. View BioDelivery Sciences International's Earnings History.
When is BioDelivery Sciences International's next earnings date?
What guidance has BioDelivery Sciences International issued on next quarter's earnings?
BioDelivery Sciences International updated its FY 2019 earnings guidance on Thursday, August, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $101-105 million, compared to the consensus revenue estimate of $101.17 million.
What price target have analysts set for BDSI?
5 analysts have issued twelve-month price objectives for BioDelivery Sciences International's stock. Their forecasts range from $5.00 to $8.00. On average, they anticipate BioDelivery Sciences International's share price to reach $6.50 in the next year. This suggests a possible upside of 26.0% from the stock's current price. View Analyst Price Targets for BioDelivery Sciences International.
What is the consensus analysts' recommendation for BioDelivery Sciences International?
What are Wall Street analysts saying about BioDelivery Sciences International stock?
Here are some recent quotes from research analysts about BioDelivery Sciences International stock:
- 1. According to Zacks Investment Research, "BioDelivery reported encouraging first-quarter results wherein earnings and sales surpassed the respective estimates. The company secured improved positioning in several managed care contracts, providing preferred access to Belbuca. The company’s efforts have brought 115 million patients under preferred coverage so far in 2019, having started 2018 with 7 million. The company’s efforts boosted the drug’s sales and the momentum is expected to continue in 2019. Belbuca’s prescriptions grew sequentially in the past few quarters. The acquisition of U.S. rights of Symproic strengthened the chronic pain portfolio. BioDelivery’s shares have outperformed the industry so far this year. However, given the lackluster performance of Bunavail, BioDelivery has decided to reduce spending on the drug. The company’s portfolio and its pipeline may face severe competition as these target a highly genericized and crowded market." (5/21/2019)
- 2. Cantor Fitzgerald analysts commented, ". Post BDSI’s recent acquisition of U.S. commercial rights to Symproic, and equity raise, we are updating our model and reiterating our Overweight rating and 12-month price target of $8. BDSI has built a strong commercial team around Belbuca, and the acquisition leverages the company’s commercial strengths, and footprint, to grow its portfolio. We view the acquisition of Symproic as a positive as it diversifies the company’s revenue away from a single product, Belbuca, and can add a meaningful revenue contribution of $75MM + without the need for any significant increase in spending." (4/16/2019)
- 3. HC Wainwright analysts commented, "Our $6 12-month target (from $5) is based on a DCF reflecting strong Belbuca growth to nearly $180M by 2022, company cash-flow breakeven by end-2019, and overall profitability in 2020. Our DCF reflects a 10% WACC discount and negative -15% terminal value beyond 2026, and includes 90M fully diluted shares vs. currently reported 70M) to account for, among other shares, the substantial dilution from convertible preferred series B shares that were issued in the 2018 $50M financing ($1.80/share conversion price)." (3/15/2019)
Has BioDelivery Sciences International been receiving favorable news coverage?
News coverage about BDSI stock has been trending somewhat positive this week, according to InfoTrie. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. BioDelivery Sciences International earned a daily sentiment score of 0.8 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for BioDelivery Sciences International.
Are investors shorting BioDelivery Sciences International?
BioDelivery Sciences International saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,240,000 shares, an increase of 6.3% from the August 30th total of 3,990,000 shares. Based on an average trading volume of 691,500 shares, the days-to-cover ratio is currently 6.1 days. Approximately 5.3% of the company's stock are sold short. View BioDelivery Sciences International's Current Options Chain.
Who are some of BioDelivery Sciences International's key competitors?
Some companies that are related to BioDelivery Sciences International include Prestige Consumer Healthcare (PBH), Apellis Pharmaceuticals (APLS), Akcea Therapeutics (AKCA), Tricida (TCDA), Deciphera Pharmaceuticals (DCPH), Uniqure (QURE), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT), Alder Biopharmaceuticals (ALDR), Insmed (INSM), Nabriva Therapeutics (NBRV), Heron Therapeutics (HRTX), Ironwood Pharmaceuticals (IRWD) and Supernus Pharmaceuticals (SUPN).
What other stocks do shareholders of BioDelivery Sciences International own?
Who are BioDelivery Sciences International's key executives?
BioDelivery Sciences International's management team includes the folowing people:
- Mr. Herm Cukier, CEO & Director (Age 52)
- Mr. Scott M. Plesha, Pres & Chief Commercial Officer (Age 54)
- Mr. James Vollins J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 50)
- Dr. Thomas B. Smith FAAFP, M.D., Chief Medical Officer (Age 58)
- Mr. Ernest Robert De Paolantonio CPA, MBA, Exec. Officer (Age 66)
Who are BioDelivery Sciences International's major shareholders?
BioDelivery Sciences International's stock is owned by a number of of institutional and retail investors. Top institutional investors include NEXT Financial Group Inc (0.17%) and Nisa Investment Advisors LLC (0.04%). Company insiders that own BioDelivery Sciences International stock include Francis E Odonnell Jr, Healthcare Master Fun Broadfin, Herm Cukier, Mark A Sirgo and Paolantonio Ernest Robert De. View Institutional Ownership Trends for BioDelivery Sciences International.
Which major investors are buying BioDelivery Sciences International stock?
How do I buy shares of BioDelivery Sciences International?
Shares of BDSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is BioDelivery Sciences International's stock price today?
One share of BDSI stock can currently be purchased for approximately $5.16.
How big of a company is BioDelivery Sciences International?
BioDelivery Sciences International has a market capitalization of $461.92 million and generates $55.64 million in revenue each year. The specialty pharmaceutical company earns $-33,870,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. BioDelivery Sciences International employs 164 workers across the globe.View Additional Information About BioDelivery Sciences International.
What is BioDelivery Sciences International's official website?
How can I contact BioDelivery Sciences International?
BioDelivery Sciences International's mailing address is 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC, 27612. The specialty pharmaceutical company can be reached via phone at 919-582-9050 or via email at [email protected]
MarketBeat Community Rating for BioDelivery Sciences International (NASDAQ BDSI)
MarketBeat's community ratings are surveys of what our community members think about BioDelivery Sciences International and other stocks. Vote "Outperform" if you believe BDSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BDSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
